文献速递银屑病与炎症性皮肤病

银屑病患者接受布罗达鲁单抗治疗的循环药物水平与治疗结局:病例系列研究

Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series.
PubMed 文献 · JAMA Dermatol · 2022-01-01

该多中心病例系列研究纳入20例既往IL-17A抑制剂治疗失败的银屑病患者,接受布罗达鲁单抗210 mg治疗。治疗12周后,可定量药物水平(≥0.05 μg/mL)患者PASI改善中位数93%,显著高于不可定量组(中位数-3,P=0.006)。未达到PASI 75者中80%药物水平不可定量,而应答者中仅21%。未检测到抗布罗达鲁单抗抗体。作者认为监测循环药物水平可能有助于临床决策。

要点

  • 治疗12周时,布罗达鲁单抗可定量(≥0.05 μg/mL)患者PASI改善中位数93%,显著高于不可定量组(中位数-3)。
  • 未达PASI 75的5例患者中4例(80%)药物水平不可定量,而14例PASI 75应答者中仅3例(21%)。
  • 7例(35%)治疗12周时药物水平不可定量的患者均未维持应答,所有检测样本未发现抗布罗达鲁单抗抗体。

核心结论

  • 作者认为循环布罗达鲁单抗水平是与临床治疗应答相关的因素。
  • 监测循环布罗达鲁单抗水平可能有助于临床决策并帮助避免无效治疗。

研究设计与样本

  • 多中心病例系列研究,纳入2018年至2020年间在丹麦根措夫特和奥胡斯大学医院皮肤科招募的既往IL-17A抑制剂治疗失败的银屑病患者。
  • 共纳入20例银屑病患者(13例[65%]为男性;中位年龄50岁,范围19-66岁)。
  • 患者在第4周和第12周进行治疗访视;12周未达到PASI 75者停药并视为无应答者;维持PASI 75应答者随访至52周。
  • 干预为布罗达鲁单抗210 mg,在第0、1、2周给药,之后每2周一次。

主要发现

  • 治疗12周后,布罗达鲁单抗可定量(≥0.05 μg/mL)患者PASI改善中位数93%(范围61%-100%),显著高于不可定量患者的中位数-3(范围-49%至94%),P=0.006。
  • 治疗12周后,未达到PASI 75的5例患者中4例(80%)药物水平不可定量(<0.05 μg/mL),而14例PASI 75应答者中仅3例(21%)出现此情况。
  • 治疗12周时药物水平不可定量的7例(35%)患者中,无1例维持应答。
  • 所有检测样本中均未检测到抗布罗达鲁单抗抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Given the possible treatment modalities in psoriasis management, little is known about whether drug monitoring is associated with response rate. OBJECTIVE: To determine whether drug monitoring is associated with response to brodalumab therapy. DESIGN: A multicenter case series study of patients with psoriasis treated with brodalumab whose treatment with previous IL-17A inhibitor therapy failed. Patients were recruited from the Departments of Dermatology at Gentofte and Aarhus University Hospitals, Denmark, between 2018 and 2020. Patient visits were conducted after 4 and 12 weeks of therapy. Patients not achieving Psoriasis Area and Severity Index 75% improvement from baseline (PASI 75) after 12 weeks were discontinued and considered nonresponders. Patients maintaining PASI 75 response were followed up for up to 52 weeks. EXPOSURE: Treatment with brodalumab, 210 mg, at weeks 0, 1, 2, then every 2 weeks. MAIN OUTCOMES AND MEASURES: Outcome measures were PASI reductions vs brodalumab levels and antibrodalumab antibodies. RESULTS: Twenty patients with psoriasis (13 [65%] were male; median age, 50 years [range, 19-66 years]) were included. After 12 weeks of therapy, patients with quantifiable levels of brodalumab (≥0.05 μg/mL) experienced significantly higher PASI reductions than those without (median, 93%; range, 61%-100% vs median, -3; range, -49% to 94%, respectively; P = .006). After 12 weeks of therapy, 4 of 5 patients (80%) not achieving PASI 75 had subquantifiable drug levels (<0.05 μg/mL), although this finding was seen for only 3 of 14 PASI 75 responders (21%). None of 7 patients (35%) with subquantifiable drug levels after 12 weeks of therapy maintained response. No antibrodalumab antibodies were detected in any of the tested samples. CONCLUSIONS AND RELEVANCE: Results of this case series study suggest that circulating brodalumab level is a factor associated with clinical treatment response. Monitoring patient levels of circulating brodalumab may aid clinical decision-making and help prevent ineffective therapy.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Enevold C, Loft N, Bregnhøj A, et al. Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series. JAMA Dermatol. 2022. PMID: 35648430. doi:10.1001/jamadermatol.2022.1863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。